MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor
19 Agosto 2024 - 6:00AM
Business Wire
- First patient dosed in a first-in-human study
to assess safety and tolerability of MOMA-313 in patients with
cancers carrying mutations in DNA repair genes -
- MOMA-313 is a highly potent and selective
oral polymerase theta helicase inhibitor, displaying best-in-class
potential -
- MOMA selects MOMA-341, a potentially best-in
class Werner helicase inhibitor, as development candidate for
second program; IND application filing anticipated in Q1 2025 -
MOMA Therapeutics, a clinical-stage biopharmaceutical company
discovering and developing a new generation of precision
therapeutics, today announced that the first patient has been dosed
in its Phase 1 clinical trial to assess the safety and tolerability
of MOMA-313, a novel, highly potent and selective oral polymerase
theta helicase inhibitor.
MOMA-313 is initially being developed in combination with a PARP
inhibitor for patients with solid tumors harboring alterations in
certain DNA repair genes, including subgroups of prostate cancer,
pancreatic cancer and breast cancer.
In parallel, MOMA announced the selection of a development
candidate for its second lead program, MOMA-341, an oral potent and
selective covalent Werner helicase inhibitor for treatment of
cancers with microsatellite instability. An IND application filing
with the FDA is anticipated in the first quarter of 2025.
“We are excited to be progressing two molecules with
best-in-class potential toward the benefit of cancer patients in
need in such close proximity,” said Asit Parikh, M.D., Ph.D., chief
executive officer of MOMA. “The advance into clinical development
for a company founded as an idea on paper a few years back is
humbling. This progress serves as a testament to the excellence and
unwavering commitment of the entire MOMA team.”
“Advancing two highly potent and selective drug candidates
derived from our proprietary KNOMATIC platform toward the clinic is
a unique privilege,” added Peter Hammerman, M.D., Ph.D., chief
scientific officer of MOMA. “The goal with each candidate is to
translate groundbreaking science into life-altering medicine.”
About MOMA-313 and the Phase 1 Trial
MOMA-313 is a potent and selective oral polymerase theta (Polθ)
helicase inhibitor. Polθ is involved in the repair of DNA
double-strand breaks that arise during DNA replication. The Phase 1
trial (NCT06545942) is a multi-center, open-label study designed to
evaluate the safety and tolerability of MOMA-313 as monotherapy and
in combination with the PARP inhibitor olaparib for patients where
a PARP inhibitor would be expected to provide benefit. Response to
PARP inhibitors can be short-lived due to primary and acquired
resistance. Pre-clinical studies suggest that combining a PARP
inhibitor with a Polθ inhibitor could afford unique mechanistic
potential to deepen and prolong that response.
About MOMA-341
MOMA is developing MOMA-341 as an oral, potent and selective
covalent inhibitor of Werner helicase with a novel chemical
scaffold as monotherapy and in combination with chemotherapy and
immunotherapy in tumors with microsatellite instability (e.g.,
colorectal, gastric, endometrial cancers).
About the KNOMATIC platform
The KNOMATIC platform integrates deep structural insights,
advanced hit-finding technologies, and computation-enabled lead
optimization to accelerate discovery of novel therapeutics
targeting families of highly dynamic proteins, such as ATPases and
GTPases. MOMA-313 and MOMA-341 were discovered and developed
through the application of the KNOMATIC platform.
About MOMA Therapeutics
MOMA Therapeutics is a clinical-stage, next-generation precision
medicine company dedicated to targeting highly dynamic proteins
that underlie human disease via a small molecule approach,
utilizing its proprietary KNOMATIC platform. The platform was
designed to exploit key vulnerabilities inherent to all dynamic
proteins, namely their dependence on well-coordinated, stepwise
changes in protein conformation. By focusing on genetically
validated targets with high translation potential, MOMA is rapidly
advancing its pipeline toward responses in the clinic. In January
2024, MOMA announced a five-year discovery collaboration with Roche
focused on critical cancer dependencies.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819758179/en/
Katie Engleman katie@1abmedia.com